About Ritter Pharmaceuticals, Inc.
Founder Andrew Ritter suffered from severe lactose intolerance since his early childhood. Medical experts told Andrew there was no treatment available and that he would have to manage suffering from lactose intolerance for the rest of his life. The condition dramatically affected his health and lifestyle, and thus he began a quest to develop a better solution for his condition after years of suffering.
Andrew assembled a team of leading lactose intolerance and gastrointestinal experts to formulate, develop and test an alternative solution for treating the condition. After identifying an early generation product which demonstrated dramatic improvement in lactose intolerance symptoms, the team embarked on a formal FDA-approval clinical development process to establish efficacy and safety to ultimately be able to provide the treatment to the billions of lactose intolerance sufferers worldwide. The therapeutic, called RP-G28, is a first-in-class compound with the potential to become the first FDA-approved drug for the treatment of lactose intolerance.
Ritter’s pioneering scientific team developed this compound based on the philosophy around colonic adaptation and the ability to improve colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem. The scientific team is especially excited for the potential of this platform to not only treat lactose intolerance, but in the future, other major gastrointestinal diseases such as irritable bowel syndrome, Crohn’s disease, ulcerative colitis and others.